Contact us
Send us your question or query through this form and we will respond as soon as possible.
Sin categorizar

Nano1Health presents preliminary results on drug-resistance biomarkers in Leishmania infantum.

The team of Nano1Health presents their preliminary results on discovery and reporting of drug-resistance biomarkers in Leishmania infantum through Nanopore sequencing at the London Calling 2022 conference, in London (UK).
By Nano1Health
1 min

London Calling 2022 poster

We were happy to share the latest advances on Leishmania infantum biomarker research at the London Calling 2022 conference from Oxford Nanopore Technologies! We used Nanopore sequencing to identify and study structural variants in the L. infantum genome to detect differences in copy number of genes related to virulence and drug resistance.

The objective of the project is the development of an agile and straightforward platform that allows sequencing L. infantum genome and must help to:

1. The search and identification of biomarkers of pathogenicity and resistance to pharmacological treatment in L. infantum for veterinary clinicians and companies in the biomedical and pharmaceutical sectors.

2. Carrying out molecular epidemiology studies to compare L. infantum strains of dogs, main reservoir around the world, and human origin.

If you have isolates of L. infantum and are willing to participate in the project, feel free to get in touch (info@nano1health.com).

1. L. infantum isolates (minimum 5x10e7 promastigotes or amastigotes).
2. L. infantum High Molecular Weight DNA (minimum 2 µg DNA – get in touch for the recommended DNA extraction method).

1. Joining an international consortium for the improved diagnostics of L. infantum biomarkers for pathogenicity and drug resistance.

Next Wednesday June the 1st it will be the Día Nacional por la Prevención de la leishmaniosis canina in Spain. Stay tuned for more news!

We care, we innovate, and we enable genomics for Global Health!

The excellence in one health genomics